Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.

Cancer genetics·2026
Same author

Serum-free mesenchymal stem/stromal cell secretomes induce embryonic stem cell gastruloid formation and cardiomyocyte development.

Biochemical and biophysical research communications·2026
Same author

Proceedings of the first international NMIBC consensus classification meeting.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

The FACT complex associates with the RPA complex at viral replication compartments to promote adenovirus infection.

Journal of virology·2026
Same author

<i>PENK</i> methylation and non-invasive bladder cancer detection.

Translational andrology and urology·2026
Same author

Pro-inflammatory diet predicts poorer survival in bladder cancer: Results from the bladder cancer prognosis programme.

Clinical nutrition (Edinburgh, Scotland)·2026
Same journal

Comprehensive bioinformatics and experimental analysis of PPOX reveals its carcinogenic effect in clear cell renal cell carcinoma.

Translational andrology and urology·2026
Same journal

Advancing urological practice: the value of combined antegrade and retrograde ureterography for the management of complex ureteral strictures.

Translational andrology and urology·2026
Same journal

N-acetylcysteine alleviates experimental autoimmune prostatitis in rats by activating PI3K/Akt/CREB and Keap1/Nrf2 pathways.

Translational andrology and urology·2026
Same journal

Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer.

Translational andrology and urology·2026
Same journal

Pulsed Thulium:YAG laser enucleation versus open simple prostatectomy for large-gland benign prostatic hyperplasia: a retrospective comparative observational study.

Translational andrology and urology·2026
Same journal

An intelligent wearable device based on electrical impedance tomography for dynamic and accurate monitoring of voiding function in patients with benign prostatic hyperplasia: protocol for a single-centre self-controlled diagnostic consistency study.

Translational andrology and urology·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.8K

Liquid biopsies for bladder cancer.

Douglas G Ward1, Richard T Bryan1

  • 1The Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Translational Andrology and Urology
|May 26, 2017
PubMed
Summary
This summary is machine-generated.

Accurate urinary biomarkers, like FGFR3 and PIK3CA mutations detected via ddPCR, show promise for non-invasive urothelial bladder cancer (UBC) detection and prognosis. High mutant cfDNA levels correlate with UBC stage, grade, size, and predict disease progression or recurrence.

Keywords:
Liquid biopsybladder cancerurinary biomarker

More Related Videos

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.6K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.8K
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.6K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Biomarker Discovery

Background:

  • Non-invasive detection of urothelial bladder cancer (UBC) is crucial for transforming patient care and reducing reliance on cystoscopy.
  • Liquid biopsies, including urinary and plasma tumor DNA (tDNA), offer a promising avenue for detecting and monitoring UBC.
  • Next-generation sequencing (NGS) and droplet digital PCR (ddPCR) are advanced techniques for detecting low levels of tDNA.

Discussion:

  • The study by Christensen et al. utilized ddPCR to detect common FGFR3 and PIK3CA mutations in urinary cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA).
  • Findings indicate a positive correlation between mutant cfDNA levels in urine and UBC tumor stage, grade, and size in non-muscle-invasive bladder cancer (NMIBC) patients.
  • High initial mutant urinary cfDNA levels were associated with future disease progression in NMIBC and recurrence in cystectomy patients, with ctDNA showing a stronger association.

Key Insights:

  • Urinary cfDNA analysis using ddPCR can serve as a prognostic biomarker for urothelial bladder cancer (UBC).
  • Mutant cfDNA levels correlate with tumor characteristics and predict disease progression and recurrence.
  • This approach holds potential for improved patient management and non-invasive monitoring of UBC.

Outlook:

  • Further validation and larger studies are needed to establish the clinical utility of urinary cfDNA biomarkers for UBC.
  • Integration of ddPCR and NGS technologies could enhance the sensitivity and scope of liquid biopsy for UBC detection.
  • These advancements may lead to personalized treatment strategies and improved outcomes for bladder cancer patients.